Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis
Poly(lactide-co-glycolide) nanoparticles (NP) containing Doxorubicin (DOX) along with a nitric oxide (NO) donor Sodium Nitroprusside (SNP) were prepared by solvent displacement. NO is expected to synergise with antileishmanial activity of DOX. Preformulation studies showed no
significant interaction between DOX and SNP. DOX and SNP loaded NP had an average size of 352 nm with 48% entrapment efficiency and a drug content of 10% w/w. Biphasic drug release was observed in vitro, with an initial burst of DOX and SNP (∼26% and 35% respectively) followed by
sustained release for over 72 hrs.
Keywords: DOXORUBICIN; LEISHMANIASIS; NANOPARTICLES (NP); NITRIC OXIDE DONORS; PHAGOCYTOSIS; RETICULOENDOTHELIAL
Document Type: Research Article
Publication date: 01 January 2011
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content